Stocks›Healthcare›CELC

CELC

CELCUITY INC.

NasdaqResearch view

$79.52+0.19%

Sep 25 close · 1D EOD · Databento

HealthcareServices-Medical Laboratories

What happened

Daily closes · dots are Wire stories

1 story has a settled receipt so far (1 on the Wire). The record starts speaking at three.

What’s next

Expected around mid November, going by its own filing history. The company has not announced a date yet. Its matching report came Nov 12, 2025 and Nov 14, 2024, after the close.

Last report

Aug 13, 2026

after the close

Every report since 2022 →

DateEventSourceNext close

Aug 26Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast CancerGlobeNewswireGlobeNewswire+3.05%
Aug 13Earnings release, after the close · 8-KSEC EDGARSEC EDGAR ↗—AWAITING

Next close = the first close after the event against the close before it. Prior-session closes only; not a call, not advice.

Follow the news. Track the move.

CELC story timeline

Company updates and connected market context, with the dated price move attached.

Stories

Direct

Sector context/Earnings

Aug 26

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

Celcuity submitted a supplemental New Drug Application to the FDA seeking approval for REVTORPYK (gedatolisib) in patients with HR+/HER2-, PIK3CA-mutant locally advanced or metastatic breast cancer after progression. The filing creates an FDA-review catalyst for CELC.

Since story

-16.4%

2026-08-26 → 2026-09-25

GlobeNewswire · 32d ago

View both sides →

Follow the news. Track the move.